IFNB1 and myeloid sarcoma: There were no significant differences in T-cell-dependent recall response (both 68% of DMF-treated patients and 73% of IFN-β-treated patients had ≥2-fold increase in IgG), lower but non-significant T-cell independent humoral response (66% of DMF-treated vs. 79% IFN-β-treated) and no differences in the response towards neoantigen, with 53% of both DMF- and IFN-β-treated MS patients developing immunity towards meningococcal C [107].